Lirafugratinib Expands FGFR2 Cholangiocarcinoma Options
FDA approved lirafugratinib for previously treated advanced FGFR2-rearranged cholangiocarcinoma, making validated molecular testing essential for identifying eligible patients and guiding targeted treatment decisions after progression.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.